Molecular dissection of TIMP3 mutation S156C associated with Sorsby fundus dystrophy

Matrix Biology

Volumn 27, Issue 5, 2008, Pages 381-392

  Fogarasi, Marton ^a   Janssen, Andreas ^a   Weber, Bernhard H F ^a   Stöhr, Heidi ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Angiogenesis; Protease activity; Sorsby fundus dystrophy; Timp3 gene targeted mice; Tissue inhibitor of metalloproteases 3 (TIMP3)

Indexed keywords

AGGRECAN; FIBRIN; PROTEIN ADAMTS 4; PROTEIN ADAMTS 5; RECOMBINANT PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRUCH MEMBRANE; CHOROID; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE; GENE MUTATION; GENE TARGETING; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; SORSBY FUNDUS DYSTROPHY; TIMP 3 GENE; WILD TYPE;

ADAM PROTEINS; AGGRECANS; AMINO ACID SUBSTITUTION; ANIMALS; CELLS, CULTURED; CHONDROCYTES; ENDOTHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION; LIVER; MACULAR DEGENERATION; MATRIX METALLOPROTEINASE 13; MICE; MICE, KNOCKOUT; MUTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PROCOLLAGEN N-ENDOPEPTIDASE; RECOMBINANT PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANIMALIA; MURINAE; MUS;

EID: 45049084310     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.matbio.2008.01.008     Document Type: Article

References (58)

1. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., Stephens P.E., Shelley C., Hutton M., Knauper V., Docherty A.J., and Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435 (1998) 39-44
2. Anand-Apte B., Pepper M.S., Voest E., Montesano R., Olsen B., Murphy G., Apte S.S., and Zetter B. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest. Ophthalmol. Vis. Sci. 38 (1997) 817-823
3. Apte S.S., Olsen B.R., and Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J. Biol. Chem. 270 (1995) 14313-14318
4. Arris C.E., Bevitt D.J., Mohamed J., Li Z., Langton K.P., Barker M.D., Clarke M.P., and McKie N. Expression of mutant and wild-type TIMP3 in primary gingival fibroblasts from Sorsby's fundus dystrophy patients. Biochim. Biophys. Acta 1638 (2003) 20-28
5. Baynes B.M., Wang D.I., and Trout B.L. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 44 (2005) 4919-4925
6. Bond M., Murphy G., Bennett M.R., Amour A., Knauper V., Newby A.C., and Baker A.H. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. J. Biol. Chem. 275 (2000) 41358-41363
7. Borland G., Murphy G., and Ager A. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes. J. Biol. Chem. 274 (1999) 2810-2815
8. Capon M.R., Marshall J., Krafft J.I., Alexander R.A., Hiscott P.S., and Bird A.C. Sorsby's fundus dystrophy. A light and electron microscopic study. Ophthalmology 96 (1989) 1769-1777
9. Chen G., and Goeddel D.V. TNF-R1 signaling: a beautiful pathway. Science 296 (2002) 1634-1635
10. Chen M., Forrester J.V., and Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. Exp. Eye Res. 84 (2007) 635-645
11. Chong N.H., Alexander R.A., Gin T., Bird A.C., and Luthert P.J. TIMP-3, collagen, and elastin immunohistochemistry and histopathology of Sorsby's fundus dystrophy. Invest. Ophthalmol. Vis. Sci. 41 (2000) 898-902
12. Clarke M., Mitchell K.W., Goodship J., McDonnell S., Barker M.D., Griffiths I.D., and McKie N. Clinical features of a novel TIMP-3 mutation causing Sorsby's fundus dystrophy: implications for disease mechanism. Br. J. Ophthalmol. 85 (2001) 1429-1431
13. Cousins S.W., Espinosa-Heidmann D.G., and Csaky K.G. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization?. Arch. Ophthalmol. 122 (2004) 1013-1018
14. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., and Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
15. Fariss R.N., Apte S.S., Olsen B.R., Iwata K., and Milam A.H. Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am. J. Pathol. 150 (1997) 323-328
16. Fariss R.N., Apte S.S., Luthert P.J., Bird A.C., and Milam A.H. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br. J. Ophthalmol. 82 (1998) 1329-1334
17. Felbor U., Stohr H., Amann T., Schonherr U., and Weber B.H. A novel Ser156Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy with unusual clinical features. Hum. Mol. Genet. 4 (1995) 2415-2416
18. Felbor U., Stöhr H., Amann T., Schönherr U., Apfelstedt-Sylla E., and Weber B.H. A second independent Tyr168Cys mutation in the tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby's fundus dystrophy. J. Med. Genet. 33 (1996) 233-236
19. Felbor U., Suvanto E.A., Forsius H.R., Eriksson A.W., and Weber B.H. Autosomal recessive Sorsby fundus dystrophy revisited: molecular evidence for dominant inheritance. Am. J. Hum. Genet. 1 (1997) 57-62
20. Fosang A.J., Stanton H., Little C.B., and Atley L.M. Neoepitopes as biomarkers of cartilage catabolism. Inflamm. Res. 52 (2003) 277-282
21. Franzke C.W., Tasanen K., Schäcke H., Zhou Z., Tryggvason K., Mauch C., Zigrino P., Sunnarborg S., Lee D.C., Fahrenholz F., and Bruckner-Tuderman L. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. EMBO J. 21 (2002) 5026-5035
22. Gehrig A., Janssen A., Horling F., Grimm C., and Weber B.H. The role of caspases in photoreceptor cell death of the retinoschisin-deficient mouse. Cytogenet. Genome Res. 115 (2006) 35-44
23. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., Schnetz-Boutaud N., Agarwal A., Postel E.A., and Pericak-Vance M.A. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
24. Handsley M.M., and Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115 (2005) 849-860
25. Hargreaves P.G., Wang F., Antcliff J., Murphy G., Lawry J., Russell R.G., and Croucher P.I. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br. J. Haematol. 101 (1998) 694-702
26. Hashimoto G., Aoki T., Nakamura H., Tanzawa K., and Okada Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett. 494 (2001) 192-195
27. Jacobson S.G., Cideciyan A.V., Bennett J., Kingsley R.M., Sheffield V.C., and Stone E.M. Novel mutation in the TIMP3 gene causes Sorsby fundus dystrophy. Arch. Ophthalmol. 120 (2002) 376-379
28. Kashiwagi M., Tortorella M., Nagase H., and Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276 (2001) 12501-12504
29. Kashiwagi M., Enghild J.J., Gendron C., Hughes C., Caterson B., Itoh Y., and Nagase H. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J. Biol. Chem. 279 (2004) 10109-10119
30. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., SanGiovanni J.P., Mane S.M., Mayne S.T., Bracken M.B., Ferris F.L., Ott J., Barnstable C., and Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
31. Knäuper V., López-Otin C., Smith B., Knight G., and Murphy G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 27 (1996) 1544-1550
32. Langton K.P., Barker M.D., and McKie N. Localization of the functional domains of human tissue inhibitor of metalloproteinases-3 and the effects of a Sorsby's fundus dystrophy mutation. J. Biol. Chem. 273 (1998) 16778-16781
33. Langton K.P., McKie N., Curtis A., Goodship J.A., Bond P.M., Barker M.D., and Clarke M. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J. Biol. Chem. 275 (2000) 27027-27031
34. Langton K.P., McKie N., Smith B.M., Brown N.J., and Barker M.D. Sorsby's fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells. Hum. Mol. Genet. 14 (2005) 3579-3586
35. Leco K.J., Khokha R., Pavloff N., Hawkes S.P., and Edwards D.R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. 269 (1994) 9352-9360
36. Lee M.H., Knauper V., Becherer J.D., and Murphy G. Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase. Biochem. Biophys. Res. Commun. 280 (2001) 945-950
37. Lee M.H., Atkinson S., and Murphy G. Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J. Biol. Chem. 282 (2007) 6887-6898
38. Lin R.J., Blumenkranz M.S., Binkley J., Wu K., and Vollrath D. A novel His158Arg mutation in TIMP3 causes a late-onset form of sorsby fundus dystrophy. Am. J. Ophthalmol. 142 (2006) 839-848
39. Mahmoodi M., Sahebjam S., Smookler D., Khokha R., and Mort J.S. Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am. J. Pathol. 166 (2005) 1733-1740
40. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 11 (2006) 1696-1701
41. -/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat. Genet. 36 (2004) 969-977
42. Nagase H., and Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 274 (1999) 21491-21494
43. Negro A., Onisto M., Grassato L., Caenazzo C., and Garbisa S. Recombinant human TIMP-3 from Escherichia coli: synthesis, refolding, physico-chemical and functional insights. Protein Eng. 10 (1997) 593-599
44. Ohuchi T., Maruoka S., Sakudo A., and Arai T. Assay-based quantitative analysis of PC12 cell differentiation. J. Neurosci. Methods 118 (2002) 1-8
45. Porter S., Clark I.M., Kevorkian L., and Edwards D.R. The ADAMTS metalloproteinases. Biochem. J. 386 (2005) 15-27
46. Pratta M.A., Scherle P.A., Yang G., Liu R.Q., and Newton R.C. Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum. 48 (2003) 119-133
47. Qi J.H., Ebrahem Q., Yeow K., Edwards D.R., Fox P.L., and Anand-Apte B. Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J. Biol. Chem. 277 (2002) 13394-13400
48. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., Baker A., and Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9 (2003) 407-415
49. Rabie T., Strehl A., Ludwig A., and Nieswandt B. Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J. Biol. Chem. 280 (2005) 14462-14468
50. Sahebjam S., Khokha R., and Mort J.S. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum. 56 (2007) 905-909
51. Soboleva G., Geis B., Schrewe H., and Weber B.H. Sorsby fundus dystrophy mutation Timp3(S156C) affects the morphological and biochemical phenotype but not metalloproteinase homeostasis. J. Cell. Physiol. 197 (2003) 149-156
52. Sorsby A., Mason M.E.J., and Gardner N. A fundus dytrophy with unusual features. Br. J. Ophthalmol. 33 (1949) 67-97
53. Tabata Y., Isashiki Y., Kamimura K., Nakao K., and Ohba N. A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby's fundus dystrophy with unusual clinical features. Hum. Genet. 103 (1998) 179-182
54. Wang Y., and Sul H.S. Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol. Cell. Biol. 26 (2007) 5421-5435
55. Wang W.M., Ge G., Lim N.H., Nagase H., and Greenspan D.S. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem. J. 398 (2006) 515-519
56. Weber B.H., Lin B., White K., Kohler K., Soboleva G., Herterich S., Seeliger M.W., Jaissle G.B., Grimm C., Reme C., Wenzel A., Asan E., and Schrewe H. A mouse model for Sorsby fundus dystrophy. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2732-2740
57. Weber B.H., Vogt G., Pruett R.C., Stohr H., and Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat. Genet. 8 (1994) 352-356
58. Yeow K.M., Kishnani N.S., Hutton M., Hawkes S.P., Murphy G., and Edwards D.R. Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol. 21 (2002) 75-88